SLDB SOLID BIOSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, SOLID BIOSCIENCES INC reported revenue of n/a, net income of −$54.8M and diluted EPS of −$0.38; for the fiscal year ended December 2025 revenue was n/a.
SLDB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$179M, net income −$174M (margin n/a), EPS −$1.99
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$130M, net income −$125M (margin n/a), EPS −$3.06
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$104M, net income −$96.0M (margin n/a), EPS −$4.83
- Fiscal year ended Dec 2022: revenue $8.09M, gross profit n/a, operating income −$106M, net income −$86.0M (margin -1062.3%), EPS −$10.10
- Fiscal year ended Dec 2021: revenue $13.6M, gross profit n/a, operating income −$72.3M, net income −$72.2M (margin -530.0%), EPS −$10.14
SLDB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$54.8M, EPS −$0.38
- Quarter ended Mar 31, 2026: revenue n/a, net income −$56.7M, EPS −$0.52
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$49.8M, EPS −$0.50
- Quarter ended Sep 30, 2025: revenue n/a, net income −$45.8M, EPS −$0.48
- Quarter ended Jun 30, 2025: revenue n/a, net income −$39.5M, EPS −$0.42
- Quarter ended Mar 31, 2025: revenue n/a, net income −$39.3M, EPS −$0.59
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$42.6M, EPS −$1.02
- Quarter ended Sep 30, 2024: revenue n/a, net income −$32.7M, EPS −$0.79
- Quarter ended Jun 30, 2024: revenue n/a, net income −$25.1M, EPS −$0.61
- Quarter ended Mar 31, 2024: revenue n/a, net income −$24.3M, EPS −$0.64
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$20.3M, EPS −$0.99
- Quarter ended Sep 30, 2023: revenue n/a, net income −$21.0M, EPS −$1.05
- Quarter ended Jun 30, 2023: revenue n/a, net income −$24.6M, EPS −$1.25
- Quarter ended Mar 31, 2023: revenue n/a, net income −$30.1M, EPS −$1.54
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$15.2M, EPS −$0.69
- Quarter ended Sep 30, 2022: revenue n/a, net income −$20.4M, EPS −$2.71
- Quarter ended Jun 30, 2022: revenue n/a, net income −$25.1M, EPS −$3.33
- Quarter ended Mar 31, 2022: revenue n/a, net income −$25.3M, EPS −$3.37
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$18.6M, EPS −$7.38
- Quarter ended Sep 30, 2021: revenue n/a, net income −$18.0M, EPS −$2.40
SLDB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$156M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$100M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$94.2M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$98.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$77.8M, share buybacks n/a
SLDB balance sheet
- Jun 30, 2026: cash $159M, total assets $421M, total liabilities $46.5M, shareholders' equity $374M
- Mar 31, 2026: cash $297M, total assets $423M, total liabilities $48.8M, shareholders' equity $374M
- Dec 31, 2025: cash $59.9M, total assets $233M, total liabilities $52.5M, shareholders' equity $180M
- Sep 30, 2025: cash $61.4M, total assets $274M, total liabilities $56.0M, shareholders' equity $218M
- Jun 30, 2025: cash $139M, total assets $308M, total liabilities $50.0M, shareholders' equity $258M
- Mar 31, 2025: cash $211M, total assets $344M, total liabilities $49.4M, shareholders' equity $294M
- Dec 31, 2024: cash $80.2M, total assets $189M, total liabilities $51.4M, shareholders' equity $137M
- Sep 30, 2024: cash $64.4M, total assets $212M, total liabilities $44.8M, shareholders' equity $167M
Is SLDB profitable?
No. SOLID BIOSCIENCES INC lost $207M over the last four quarters.
What is SLDB's EPS?
Diluted earnings per share over the last four quarters were −$1.88; −$0.38 in the latest quarter.